Gossamer Bio, Inc. focuses on discovering, acquiring, developing, and commercializing therapeutics in immunology,inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor. GB5121, an oral, irreversible, covalent, small. molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central. central central nervous system lymphoma.
